Morepen LaboratoriesNSE:MOREPENLAB -1.20%75 3-Year ROIIC % is 5.25 as of Mar. 2026, which is 7% above its 10-year median of 4.90. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 75/100 and a GF Value™ of ₹49.87 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 943 Drug Manufacturers companies, Morepen Laboratories ranks better than 51.96% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Morepen Laboratories's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 5.25%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Morepen Laboratories's 3-Year ROIIC % or its related term are showing as below:
NSE:MOREPENLAB's 3-Year ROIIC % is ranked better than 51.96% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.74
vs NSE:MOREPENLAB: 5.25
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Morepen Laboratories 3-Year ROIIC % Related Terms
Morepen Laboratories 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MOREPENLAB vs ZTS, UTHR: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Morepen Laboratories (NSE:MOREPENLAB) has a 3-Year ROIIC % of 5.25 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Morepen Laboratories and its competitors. This is near median its historical median of 4.90. Over the past decade, Morepen Laboratories' 3-Year ROIIC % has ranged from 0.16 to 57.89. According to the industry distribution chart, Morepen Laboratories ranks #453 out of 943 companies in the Drug Manufacturers industry, placing it in the top 48%.
Is Morepen Laboratories' 3-Year ROIIC % too high?
Morepen Laboratories' current 3-Year ROIIC % of 5.25 is near median its 10-year median of 4.90. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 57.89. The Drug Manufacturers industry median 3-Year ROIIC % is 3.74. Morepen Laboratories' value of 5.25 is 40.4% above this industry median. Based on the distribution chart, Morepen Laboratories ranks #453 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #453 out of 943 companies for 3-Year ROIIC %. This puts Morepen Laboratories in the upper half of its industry. The industry median 3-Year ROIIC % is 3.74. Morepen Laboratories' value of 5.25 is 40.4% above this benchmark. Historically, Morepen Laboratories' own 3-Year ROIIC % has ranged from 0.16 to 57.89 over the past decade. While the company's 10-year median is 4.90 vs. the industry median of 3.74, Morepen Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current 3-Year ROIIC % of 5.25 is 40.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current 3-Year ROIIC % is 5.25, which is near median its own 10-year median of 4.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹49.87, compared to a current price of ₹59.07 — trading 18.4% above its estimated fair value. The current 3-Year ROIIC % is 5.25, which is near median its 10-year median of 4.90 and 40.4% above the Drug Manufacturers industry median of 3.74. Morepen Laboratories' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current 3-Year ROIIC % is 5.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹59.07 is trading 18.4% above its estimated GF Value™ of ₹49.87.
GuruFocus considers Morepen Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
3-Year ROIIC %: 5.25 (near median its 10-year median of 4.90)
GF Value™: ₹49.87 vs. price of ₹59.07 (18.4% above fair value)
Industry Position: 40.4% above the Drug Manufacturers median (#453 of 943)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
75GF Score
Get the complete analysis for NSE:MOREPENLAB
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
